The age of blockbusters is over; the solution lies in the 4 Ps: personalised, participatory, preventive and predictive. With Zühlke as your partner, you can boldly drive this development forward – with digital, data-driven solutions that add value for you and your patients.
In the healthcare market of tomorrow, the key to success will be applying pharmaceutical and health tech expertise to unmet patient need. The future will belong to innovative solutions spanning the entire patient journey and – crucially – which deal with patient data responsibly.
Machine learning algorithms represent an exciting approach for realising new products and services or for process optimisation. Realising the potential offered by machine learning requires platforms that enable secure, legal, privacy-preserving use of anonymised health data.
With no side effects and high scalability, digital therapeutics (DTx) boast enormous potential – including for pharmaceutical companies. That’s because software that is used as a therapeutic product is able to target new customer groups and enable completely new business and payment models.
Whether it’s clinical trials or pay for performance, as digitalisation of the healthcare system progresses, continuous monitoring of therapeutic progress and outcomes is set to become increasingly important. That necessitates smart, reliable sensors able to measure and transmit biomarker information.
For pharmaceutical companies, clinical trials represent a significant cost. GxP-compliant data platforms can help companies design safe, reliable trials in the shortest possible time, and help them find the right participants.
Big tech has inserted itself into every aspect of our lives and is collecting user data on an unprecedented scale. This throws up some major challenges for pharmaceutical companies. Patients, health insurers and society in general expect ever more – from more personalised medicine to complementary digital health services, to outcome-based payment models (pay for performance).
Zühlke offers both extensive expertise in the development of large B2C consumer platforms and more than 50 years of experience in the healthcare sector. We’re developing apps and devices for the next phase of personalised healthcare, and helping pharmaceutical companies position themselves to play a lead role in tomorrow’s digitalised healthcare system.
Machine learning algorithms enable the development of exciting new products and services and well as improving therapy selection and process acceleration through the use of genetic or real-world data. In addition to our expertise in machine-learning algorithms, Zühlke also develops platforms to enable secure, legal use of anonymised health data – an important basis for research and development as well as a positive digital experience for patients.
That requires trust between patients, researchers and the companies providing these solutions – which Zühlke achieves by giving patients complete control over their health data. To realise this, we bring together user-centric healthcare apps for patients, data security expertise, advanced machine-learning techniques like federated learning, and insights from the behavioural sciences.
Drugs sometimes have serious side effects that can be highly onerous for patients. Digital therapeutics (DTx) offer huge potential for addressing this problem, for example in areas such as mental health.
Zühlke can help you realise your digital healthcare ideas – from feasibility studies through to operation of your solution. The result is software as a medical device (SaMD) products capable of supplementing or even replacing existing therapies and diagnostic procedures. Enabling pharmaceutical companies to target new customer groups and develop completely new business and payment models (in Germany, for example, through digital health and digital care apps).
And, in contrast to conventional drugs, bringing digital therapeutics to market is quick, simple and easily rolled out globally. We help you grasp this opportunity with secure, patient-centric apps that comply with exacting medical standards like IEC 62366-1.
In today’s healthcare, proving the efficacy of a new drug through clinical trials is no longer sufficient – you need to prove beyond doubt that it’s superior to existing treatments. As with outcome-based payment models (pay for performance), pharmaceutical companies are increasingly required to measure the benefits of a therapy in real time.
We can help you achieve this by, for example, developing smart sensors for measuring digital biomarkers. Our solutions are always based on established processes and subject to constant controls during development. We also help you exploit your harvested data – whether by developing and operating a full scale digital data platform, by using machine learning to extract valuable information from your captured data or by using user-friendly apps to add patient reported outcomes (PRO) to your data pool.
With overcomplicated registration processes and high drop-out rates, clinical trials are often inefficient and time-consuming. So much so that clinical trials can consume up to 50 percent of a pharmaceutical company’s R&D budget. By helping pharmaceutical companies identify suitable participants and making it easier for participants to take part in trials, digital technologies have the power to solve this problem. Zühlke’s GxP-compliant data platforms enable safe, reliable trials to be designed in the shortest possible time.
Using our AI expertise, we can help you extract key information from your harvested data. And we enhance the participant experience by offering attractive apps and user-friendly participant portals – bringing you closer to your patients, but also closer to doctors and other healthcare professionals. And we make sure our solutions meet the highest security standards, boosting trust in your company.
Join us to learn how inspiring individuals from diverse fields and industries are transforming the way they work with data to realise their greatest opportunities. Learn more about data transparency and education in the episode with Anne Thielen.
The life sciences and healthcare industries are producing an ever increasing amount of data – DHPs hold the key to harnessing it.
As one of the first employees at Zühlke Germany, Jürgen Pronebner has helped to shape the Zühlke journey. Currently he acts as MD for Business Development and Business Innovation Consulting. He is a Member of the Zühlke Ventures Advisory Board and a long-time Partner in the Zühlke Group.
Together with his team, Albert Frömel helps his clients improve health outcomes for patients, modernise work environments, and future-proof business models. As a Healthcare and Life Sciences Industry Lead in Austria, he helps find solutions to key digital challenges. He has years of experience working with leading national and international healthcare organisations.
Nicolas oversees the Healthcare and MedTech vertical at Zuhlke Singapore. As part of the Business Development team, he works on digital innovation initiatives together with both global and local customers. Nicolas finds joy in helping clients connect the dots, from conceptualisation to creation of exciting products.
Bardia M. Zanganeh serves leading healthcare institutions on all technology agenda issues. His primary areas of focus include digital innovation, business model transformation and product innovation. He has a background in engineering, consulting and entrepreneurship and is a lecturer at the University of Applied Sciences in Business Administration in Zurich. He is driven by the positive impact of technology to reimagine healthcare for better patient outcomes.